Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized study

Cardiovascular Diabetology

Volumn 9, Issue , 2010, Pages

  Kveiborg, Britt ^a   Hermann, Thomas S ^b   Major Pedersen, Atheline ^b   Christiansen, Buris ^a   Rask Madsen, Christian ^c   Raunsø, Jakob ^b   Køber, Lars ^d   Torp Pedersen, Christian ^b   Dominguez, Helena ^b  

^a NAESTVED HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c JOSLIN DIABETES CENTER   (United States)

^d Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; INSULIN; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; SEROTONIN; SEROTONIN AGONIST; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; METOPROLOL; NITROPRUSSIDE SODIUM; PROPANOLAMINE DERIVATIVE; VASODILATOR AGENT;

ADULT; ARTICLE; BLOOD VESSEL REACTIVITY; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIABETIC PATIENT; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG INFUSION; ENDOTHELIUM; FEMALE; FOREARM BLOOD FLOW; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN ALLERGY; STROKE; SYSTOLIC BLOOD PRESSURE; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY; BLOOD; BLOOD FLOW; DENMARK; DOSE RESPONSE; FOREARM; INSULIN RESISTANCE; INTRAARTERIAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHOTOELECTRIC PLETHYSMOGRAPHY; TIME; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; DENMARK; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; FOREARM; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRA-ARTERIAL; INSULIN; INSULIN RESISTANCE; MALE; METOPROLOL; MIDDLE AGED; NITROPRUSSIDE; PHOTOPLETHYSMOGRAPHY; PROPANOLAMINES; REGIONAL BLOOD FLOW; SEROTONIN; TIME FACTORS; TREATMENT OUTCOME; VASODILATION; VASODILATOR AGENTS;

EID: 77954301050     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-9-21     Document Type: Article

References (36)

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853. 10.1016/S0140-6736(98)07019-6, 9742976.
2. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT, Oakes R, Lukas MA, Anderson KM, Bell DS. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. Jama 2004, 292:2227-2236. 10.1001/jama.292.18.2227, 15536109.
3. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003, 362:7-13. 10.1016/S0140-6736(03)13800-7, 12853193.
4. Torp-Pedersen C, Metra M, Charlesworth A, Spark P, Lukas MA, Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Remme WJ, Scherhag A. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart 2007, 93:968-973. 10.1136/hrt.2006.092379, 17237130.
5. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999, 340:115-126. 10.1056/NEJM199901143400207, 9887164.
6. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001, 104:2673-2678. 10.1161/hc4601.099485, 11723017.
7. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996, 97:2601-2610. 10.1172/JCI118709, 507347, 8647954.
8. Rask-Madsen C, Ihlemann N, Krarup T, Christiansen E, Kober L, Nervil Kistorp C, Torp-Pedersen C. Insulin therapy improves insulin-stimulated endothelial function in patients with type 2 diabetes and ischemic heart disease. Diabetes 2001, 50:2611-2618. 10.2337/diabetes.50.11.2611, 11679442.
9. Utriainen T, Malmstrom R, Makimattila S, Yki-Jarvinen H. Methodological aspects, dose-response characteristics and causes of interindividual variation in insulin stimulation of limb blood flow in normal subjects. Diabetologia 1995, 38:555-564. 10.1007/BF00400724, 7489838.
10. Vehkavaara S, Makimattila S, Schlenzka A, Vakkilainen J, Westerbacka J, Yki-Jarvinen H. Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 2000, 20:545-550.
11. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004, 27(Suppl 1):S5-S10.
12. Hermann TS, Li W, Dominguez H, Ihlemann N, Rask-Madsen C, Major-Pedersen A, Nielsen DB, Hansen KW, Hawkins M, Kober L, Torp-Pedersen C. Quinapril treatment increases insulin-stimulated endothelial function and adiponectin gene expression in patients with type 2 diabetes. J Clin Endocrinol Metab 2006, 91:1001-1008. 10.1210/jc.2005-1231, 16352688.
13. Dominguez H, Storgaard H, Rask-Madsen C, Steffen Hermann T, Ihlemann N, Baunbjerg Nielsen D, Spohr C, Kober L, Vaag A, Torp-Pedersen C. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 2005, 42:517-525. 10.1159/000088261, 16155368.
14. Jawa A, Nachimuthu S, Pendergrass M, Asnani S, Fonseca V. Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension. J Diabetes Complications 2008, 22:303-308. 10.1016/j.jdiacomp.2007.05.003, 2590589, 18413195.
15. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989, 2:997-1000. 10.1016/S0140-6736(89)91013-1, 2572793.
16. Pyorala M, Miettinen H, Halonen P, Laakso M, Pyorala K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol 2000, 20:538-544.
17. Verma S, Arikawa E, Yao L, Laher I, McNeill JH. Insulin-induced vasodilation is dependent on tetrahydrobiopterin synthesis. Metabolism 1998, 47:1037-1039. 10.1016/S0026-0495(98)90273-6, 9751228.
18. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996, 14:489-494. 10.1097/00004872-199604000-00012, 8761899.
19. Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, De Angelis L, D'Onofrio F. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997, 126:955-959.
20. Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Bmj 1989, 298:1152-1157. 10.1136/bmj.298.6681.1152, 1836369, 2500169.
21. Pischon T, Sharma AM. Use of beta-blockers in obesity hypertension: potential role of weight gain. Obes Rev 2001, 2:275-280. 10.1046/j.1467-789X.2001.00044.x, 12119998.
22. Vozarova B, Stefan N, Lindsay RS, Krakoff J, Knowler WC, Funahashi T, Matsuzawa Y, Stumvoll M, Weyer C, Tataranni PA. Low plasma adiponectin concentrations do not predict weight gain in humans. Diabetes 2002, 51:2964-2967. 10.2337/diabetes.51.10.2964, 12351434.
23. Schulze MB, Shai I, Rimm EB, Li T, Rifai N, Hu FB. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005, 54:534-539. 10.2337/diabetes.54.2.534, 15677512.
24. Celik T, Iyisoy A, Kursaklioglu H, Kardesoglu E, Kilic S, Turhan H, Yilmaz MI, Ozcan O, Yaman H, Isik E, Fici F. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006, 24:591-596. 10.1097/01.hjh.0000209993.26057.de, 16467663.
25. von zur Muhlen B, Millgard J, Lind L. Divergent effects of different beta-blocking agents on endothelium-dependent vasodilatation in the human forearm. Blood Press 2000, 9:287-292. 10.1080/080370500448687, 11193133.
26. von zur Muhlen B, Kahan T, Hagg A, Millgard J, Lind L. Treatment with irbesartan or atenolol improves endothelial function in essential hypertension. J Hypertens 2001, 19:1813-1818. 10.1097/00004872-200110000-00015, 11593101.
27. Hess OM, Bortone A, Gaglione A, Nonogi H, Grimm J, Krayenbuehl HP. Effect of intracoronary and intravenous propranolol on human coronary arteries. Eur Heart J 1989, 10(Suppl F):153-158.
28. Bortone AS, Hess OM, Gaglione A, Suter T, Nonogi H, Grimm J, Krayenbuehl HP. Effect of intravenous propranolol on coronary vasomotion at rest and during dynamic exercise in patients with coronary artery disease. Circulation 1990, 81:1225-1235.
29. Matsuda Y, Akita H, Terashima M, Shiga N, Kanazawa K, Yokoyama M. Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease. Am Heart J 2000, 140:753-759. 10.1067/mhj.2000.110093, 11054621.
30. Yue TL, Cheng HY, Lysko PG, McKenna PJ, Feuerstein R, Gu JL, Lysko KA, Davis LL, Feuerstein G. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992, 263:92-98.
31. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, Jankowski M, Martyniec L, Angielski S, Malinski T. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 2003, 107:2747-2752. 10.1161/01.CIR.0000066912.58385.DE, 12742996.
32. Afonso RA, Patarrao RS, Macedo MP, Carmo MM. Carvedilol action is dependent on endogenous production of nitric oxide. Am J Hypertens 2006, 19:419-425. 10.1016/j.amjhyper.2005.11.011, 16580580.
33. Giugliano D, Marfella R, Acampora R, Giunta R, Coppola L, D'Onofrio F. Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension. Diabetes Care 1998, 21:631-636. 10.2337/diacare.21.4.631, 9571355.
34. Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF, Vita JA. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996, 93:1107-1113.
35. Bank AJ, Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy JM. Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hypertens 2007, 20:777-783. 10.1016/j.amjhyper.2007.01.019, 17586413.
36. Lipinski B. Pathophysiology of oxidative stress in diabetes mellitus. J Diabetes Complications 2001, 15:203-210. 10.1016/S1056-8727(01)00143-X, 11457673.